APUS Apimeds Pharmaceuticals US, Inc.
NYSE · SEC CIK 1894525 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 23 since 2025-05-14, latest 2025-11-13
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| No open-market trades in the last year. | |||
Transactions 8
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMA | 2025-06-11 | 2025-05-12 | APUS | Inscobee Inc. | 10% | C - Cnv Deriv | $2.60 | +115.1K | 2.06M | +6% | +$299.3K |
| D | 2025-05-20 | 2025-05-16 | APUS | Emerson Erik C. | CEO, Dir | A - Grant | $0.00 | +750.0K | 750.0K | New | $0 |
| 2025-05-20 | 2025-05-16 | APUS | Kim Christopher | COB, CMO, Dir | A - Grant | $0.00 | +250.0K | 277.5K | +909% | $0 | |
| M | 2025-05-15 | 2025-05-13+ | APUS | Kim Christopher | COB, CMO, Dir | P - Purchase | $1.83 | +27.5K | 19.8K | New | +$50.4K |
| D | 2025-05-14 | 2025-05-12 | APUS | Inscobee Inc. | 10% | C - Cnv Deriv | $2.60 | +44.0K | 2.03M | +2% | +$114.5K |
| DMI | 2025-05-14 | 2025-05-12 | APUS | Inscobee Inc. | 10% | C - Cnv Deriv | $2.60 | +253.1K | 4.32M | +6% | +$658.0K |
| D | 2025-05-14 | 2025-05-12 | APUS | Inscobee Inc. | 10% | P - Purchase | $4.00 | +500.0K | 1.98M | +34% | +$2.00M |
| 2025-05-14 | 2025-05-12 | APUS | Koo Jakap | Dir | P - Purchase | $1.99 | +28.5K | 643.9K | +5% | +$56.7K |
Purchase Sale Sale after option exercise All abbreviations